Kura Oncology Stock Hits Day Low of $9.23 Amid Price Pressure

Kura Oncology, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced significant volatility today, with the stock hitting an intraday low of USD 9.23. The company’s stock has declined by 8.28% on July 28, 2026, contrasting sharply with the S&P 500's modest gain of 0.21% for the same day. Over the past week, Kura Oncology has seen a notable drop of 14.51%, while its performance over the last month reflects a decrease of 14.59%. Despite a year-over-year increase of 50.28%, the stock has faced challenges in recent months, with a year-to-date decline of 10.39%. Financial metrics indicate a concerning trend, with net sales for the half-year at USD 35.6 million, down 47.64%. The return on capital employed (ROCE) stands at a low -124.74%, and pre-tax profit has fallen by 28.18%. The stock's performance over three years shows a decline of 6.62%, and over five years, it has decreased by 50.95%. Kura Oncology's market capitalization is approximately USD 684 million, and it currently does not offer a dividend.